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Precisely how SSRIs induce long-term modifications in serotonin transmission to elicit their antidepressant
actions is unclear. In this issue ofNeuron, Issler et al. (2014) identify a key role for microRNA-135a in the raphe
nuclei in the molecular mechanisms underlying the therapeutic actions of SSRIs.Serotonin-selective reuptake inhibitors
(SSRIs) are the current first-line treatment
for major depressive disorder (MDD) and
other mood disorders including general-
ized anxiety disorder (GAD). SSRIs bind
to the serotonin transporter (SERT) and
thereby inhibit the clearance of serotonin
(5-HT) from the synaptic cleft. This trig-
gers a complex cascade of signaling
events that ultimately results in downre-
gulation of SERT and also serotonin 1A
(5-HT1A) autoreceptors on serotonergic
neurons in the raphe nuclei (RN). In turn,
these adaptive responses increase sero-
tonergic neuronal firing and elevate extra-
cellular levels of 5-HT in terminal brain
regions such as the hippocampus and
prefrontal cortex (PFC), an action consid-
ered critical to the therapeutic effects of
SSRIs. However, the mechanisms by
which chronic SSRI treatment downregu-
late SERT and 5-HT1A receptor levels to
induce long-lasting alterations in seroto-
nergic transmission are unclear.
Evidence suggests a role for altered
patterns of gene expression in mediating
the long-term therapeutic effects of
SSRIs. Much interest has focused re-
cently on the potential involvement of
microRNA-mediated regulation of gene
expression in this process. MicroRNAs
(miRNAs) are small noncoding RNAs that
bind to the 30 UTR of target mRNAs,
causing mRNA destabilization and/or
translational inhibition (Bartel, 2009).
MicroRNAs have widespread roles in the
physiology of the CNS (Mehler and
Mattick, 2007; O’Carroll and Schaefer,
2013). Furthermore, microRNAs are impli-
cated in a range of psychiatric disorders
(Mellios and Sur, 2012; Miller andWahles-
tedt, 2010), including anxiety and de-
pression (Hansen and Obrietan, 2013;
O’Connor et al., 2012; Serafini et al.,2014). Recent findings have also in-
creased interest in the potential involve-
ment of microRNAs in antidepressant
drug action. In particular, it was shown
recently that miR-16 targets SERT and
may contribute to the actions of SSRIs
(Baudry et al., 2010). Further, miR-1202
is a primate-specific miRNA associated
with MDD and responsiveness to SSRIs
(Lopez et al., 2014). In this issue of
Neuron, Issler et al. (2014) provide
compelling evidence further implicate
microRNAs in the pathophysiology of
depression and in regulating the actions
of SSRIs.
As serotonergic neurons of the dorsal
raphe nucleus (DRN) are implicated in
depression and SSRI action, Issler et al.
(2014) first investigated the microRNA
expression profile of 5-HT neurons in
this brain region by taking advantage of
a mouse line that expresses the fluores-
cent protein YFP specifically in seroto-
nergic neurons. Fluorescence cell sorting
generated two neuronal populations from
the embryonic DRN: YFP-positive 5-HT
neurons and nonfluorescent cells includ-
ing inhibitory neurons and glia. The
miRNA profile of 5-HT versus non-5-HT
cells was compared, and those with at
least a 2-fold difference in expression in
either group were chosen for further anal-
ysis. Of these miRNAs, miR-135, was of
particular interest as its expression was
relatively lower in the 5-HT neuron popu-
lation, suggesting that it could potentially
contribute to the phenotype of these cells.
Moreover, gene transcripts predicted to
be targeted by this microRNA included
SERT (Slc6a4) and the 5-HT1A autore-
ceptor (Htr1a). Consistent with these
predictions, miR-135a and its ortholog
miR-135b were shown to substantially
downregulate expression of a luciferaseNeuronreporter conjugated to the 30 UTR of
Slc6a4 or Htr1a. Mutation of the putative
binding site for miR-135 in these 30 UTRs
abrogated miRNA repression, suggesting
that these transcripts are indeed direct
targets of miR-135.
Of the two miR-135 alleles found in
mice, miR-135a is more highly expressed
in adult mouse DRN than miR-135b.
Because both miR-135a and antidepres-
sant treatment negatively regulate ex-
pression of SERT and 5-HT1A, Issler
et al. (2014) next investigated whether
miR-135a levels are altered in a mouse
model of depression or after antidepres-
sant administration and can thereby influ-
ence mood. Chronic social defeat, in
which mice are exposed to long-term
aggressive behavior from another mouse,
can induce some depression-related be-
haviors that respond to antidepressants
(Russo and Nestler, 2013). These behav-
iors include social avoidance, anhedonia,
and anxiety-like behaviors. While chronic
social defeat per se did not alter miR-
135a levels, acute or chronic treatment
with the tricyclic antidepressant imipra-
mine or the SSRI fluoxetine increased
miR-135a expression in the raphe nuclei
in control mice and in mice that had
undergone social defeat. By contrast,
the noradrenaline reuptake inhibitor anti-
depressant drug reboxetine did not alter
miR-135a levels, suggesting that miR-
135a expression is preferentially sensitive
to serotonergic transmission.
To investigate the function of miR-135a
in serotonergic neurons in vivo, Issler et al.
(2014) generated a Cre-dependent miR-
135a overexpressing mouse line that
was bred with mice expressing Cre spe-
cifically in serotonergic neurons. In agree-
ment with the luciferase assays, levels of
SERT and 5-HT1A were decreased at83, July 16, 2014 ª2014 Elsevier Inc. 253
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Previewsthe mRNA and protein level in the
miR-135a-overexpressing mice. Because
decreased expression of these genes is
thought to underlie their antidepressant
effects of SSRIs, it was hypothesized
that miR-135a could contribute to their
mechanism of action. Consistent with
this possibility, miR-135a overexpression
enhanced the resilience ofmice to chronic
social defeat. This was reflected by the
fact that anxiety- and depression-like be-
haviors were detected in the elevated
plus-maze, dark-light emergence test
and forced swim test in wild-type mice
but not in miR-135a overexpressing
mice. There was also an increase in sero-
tonin turnover in key brain regions impli-
cated in depression in the overexpressing
mice including the hippocampus and
PFC. Moreover, viral-mediated knock-
down of miR-135a in raphe resulted in
increased expression levels of SERT and
5-HT1A and increased anxiety-like be-
haviors. Interestingly, miR-135a knock-
down attenuated the efficacy of an SSRI
to reduce immobility in the forced swim
task consistent with SSRIs acting at
least in part through miR-135a. It is inter-
esting to note that previous studies have
found that approximately one-third of
mice are resilient to the negative affective
consequences of chronic social defeat
stress. Hence, it will be interesting to
determine whether endogenous miR-
135a levels are relatively higher in those
mice shown to have a resilience pheno-
type or lower in those that demonstrate
increased vulnerability to depression-like
behaviors.
These findings suggest that upregula-
tion of miR-135a in the raphe contributes
to the therapeutic actions of SSRIs, but
these findings are based on observations
in rodents. Depression is notoriously diffi-
cult to model in rodents because of com-254 Neuron 83, July 16, 2014 ª2014 Elsevierplex and unclear origins, its highly hetero-
geneous symptoms, and the inability to
determine whether such core symptoms
as sadness and even suicidality can be
manifest in rodents. Therefore, to investi-
gate whether their findings may extend
to depression in human subjects, Issler
et al. (2014) next assessed miR-135a
levels in the brains of depressed human
patients who had committed suicide.
Consistent with a role for miR-135a in
the disorder, it was found that levels of
the miRNA were decreased in the raphe
nuclei of suicide victims. Circulating levels
ofmiR-135awere also lower in the plasma
of depressed patients, suggesting that
thismicroRNA could serve as a diagnostic
and perhaps even prognostic biomarker
for the disorder.
These intriguing findings provide further
support for the involvement of miRNAs in
MDD and the mechanism of action of
antidepressant drugs. Important future
questions include identifying precisely
which neurons express miR-135a in
adults, as the neuronal subtype express-
ing endogenous miR-135a in adult was
not examined. Also, the molecular and
behavioral consequences of miR-135a
overexpression do suggest a predomi-
nantly serotonergic function; however, a
direct or indirect role in other cell types
such as noradrenergic neurons, which
also express SERT, cannot be ruled out.
Indeed, SSRI treatment differentially reg-
ulates miR-16, which also targets SERT,
in noradrenergic and serotonergic popu-
lations in the locus coeruleus and dorsal
raphe nucleus, respectively. The signaling
pathway causing miR-135a upregulation
downstream of SSRI action remains un-
clear, but an analysis of transcription
factor binding sites in the promoter of
miR-135a could shed light on potential
mechanisms. SSRI-mediated inductionInc.of miR-135a expression could be a
secondary consequence of increased
extracellular 5HT levels and subsequent
activation of 5-HT1A receptors. Perhaps
miR-135 acts endogenously in a homeo-
static mechanism that ensures the correct
balance of 5-HT1A receptors and SERT
expression. This could be explored in
the future by selectively manipulating the
activation or levels ofHtr1a and observing
whether this in itself can alter miR-135a
expression.REFERENCES
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